As a psychiatrist who has cancer, I have developed a deep understanding of the ways in which our training can help us help patients who find themselves forced to deal with the complicated emotional aspects that accompany this disease. My hope is that my insights will help psychiatrists as they wrestle with the problems that plague their patients who are coping with this difficult disease.
Polymerase Chain Reaction (PCR) testing for BCR-ABL has become the primary method used to monitor leukemia levels in CML patients. As a CML patient for almost 5 years, and someone who is in regular contact with other CML patients from around the world, I continually see the confusion that surrounds this very important issue.
Kicking off the first in a series of podcasts, a noted healthcare consultant discusses how retirement can fracture a practice.
An issue causing a lot of confusion among oncologists and their patients is Polymerase Chain Reaction (PCR) testing, and specifically, how the results are reported and interpreted.
Understandably, oncologists are reluctant to tell patients that there is no longer any benefit for them to continue chemotherapy. It is a conversation that alters the doctor/patient relationship, an acknowledgement by the doctor that, despite all the advances of modern medicine, “I can do nothing more to extend your life.” However, according to ongoing research, this difficult conversation is not being had enough, and patients, clinging to false hope, are being given chemotherapy when it should have been discontinued in favor of palliative care.
ONCOLOGY board member Judd Moul, MD, told the CancerNetwork blog that there will be several controversial pro-con debates featured at this year’s Society of Urologic Oncology (SUO) meeting, May 29th in San Francisco. Dr. Moul will moderate a pro-con debate about the effectiveness of PSA screening during a session titled, Prostate Cancer I – Screening: Lessons from the PLCO and ESRPC Randomized Trials. Stand by for exclusive interviews and podcasts…
Almost 3 years after a controversial FDA denial, Provenge was approved, making it the first autologous cellular immunotherapy for prostate cancer. One pressing question about Provenge is how much its maker, the biotech company, Dendreon, would charge for its newly approved drug.
A new study supports previous findings that finasteride prevents prostate cancer. However, like much research in prostate cancer, the study leaves us with as many questions as answers.
It’s not an outcome Dr. Harold Freeman, President and Founder, Ralph Lauren Center for Cancer Care and Prevention, or anyone else could have imagined, but since cancer patient navigators were introduced in the 1990s, we’re seeing battles and competition over just about every aspect of it.
Studies have shown that 90% of patients with advanced cancer experience severe pain. Studies have also found that more than 50% of patients are undertreated for their cancer pain. Considering that we have the ability to properly manage the great majority of cancer pain, why are so many of our patients suffering needlessly?